Special Serologic Reagents and Methods

Antihuman globulin reagents

Antihuman globulin (AHG) binds the human IgG and complement fragments named on the reagent label. The direct antiglobulin test (DAT) detects coating acquired by red cells in the circulation. The indirect antiglobulin test (IAT) produces sensitization during incubation in the laboratory, then detects the bound globulin after the applicable washing or separation step.^{1,21 Bloch EM, et al. Technical Manual. 2026.2 Diagast. Anti-Human Globulin Anti-IgG, Anti-C3d, and Anti-IgG,-C3d…}

AHG products may use polyclonal, monoclonal, or blended antibodies. The antibody source affects epitope coverage and product performance, so choose a reagent by its label and instructions for use. An anti-C3d reagent has no anti-C4 activity unless the product separately states that coverage. Interpret a reactive DAT or IAT with hemolysis evidence, transfusion and pregnancy history, drug exposure, and the reaction pattern.^{1,21 Bloch EM, et al. Technical Manual. 2026.2 Diagast. Anti-Human Globulin Anti-IgG, Anti-C3d, and Anti-IgG,-C3d…}

Tube-test controls and failure points

In a conventional tube IAT, incubation permits antibody uptake, saline washes remove unbound protein, AHG is added promptly, and calibrated centrifugation produces the endpoint. A negative result is valid only when the procedure's IgG-sensitized control cells agglutinate after their addition. Complement-detecting methods also use appropriate complement-sensitized controls at the frequency specified by the procedure. If a required control fails, repeat the test. Agglutination of the control cells confirms that the AHG remained active. Each product supplies its own cell concentration, serum or plasma volume, incubation, wash, centrifugation, reading, and daily quality control requirements.^{2,32 Diagast. Anti-Human Globulin Anti-IgG, Anti-C3d, and Anti-IgG,-C3d…3 Alba Bioscience Limited. Anti-Human Globulin Anti-IgG Instructions for Use.}

For example, the Alba Bioscience tube anti-IgG reagent uses 2 drops of serum or plasma with 1 drop of a 2% to 4% red-cell suspension, incubates at 37 ± 1 °C for 30 to 60 minutes, washes 3 to 4 times, and then centrifuges the AHG test at 900 to 1,000 × g for approximately 10 seconds. These values apply only to that product. A local procedure follows the instructions for the reagent in use.^{33 Alba Bioscience Limited. Anti-Human Globulin Anti-IgG Instructions for Use.}

The Blood Group Immunology lesson explains IgG sensitization, enhancement media, reaction phases, and complement. The pretransfusion testing process places these methods within antibody investigation and unit selection.

Enzymes, enhancement media, and lectins

Proteolytic enzymes such as ficin and papain alter red-cell membrane proteins and can strengthen, weaken, or remove antigen expression. Compare an enzyme-treated panel with untreated cells from the same investigation. A reaction that disappears suggests an antibody directed against an enzyme-sensitive antigen. A stronger reaction can reveal an enzyme-enhanced specificity. Exclude antibodies to antigens the enzyme weakens or destroys with the untreated panel, because the treated cells have lost those antigens.^{1,41 Bloch EM, et al. Technical Manual. 2026.4 Raman L, et al. Principles of laboratory techniques. 2020.}

Enzyme effects vary with the reagent and procedure. An enzyme panel is a supplemental method with its own controls. Albumin, low-ionic-strength solution (LISS), and polyethylene glycol (PEG) change the sensitization environment without enzymatically altering antigen expression. Use them as specified by the validated antibody-detection system.^{1,41 Bloch EM, et al. Technical Manual. 2026.4 Raman L, et al. Principles of laboratory techniques. 2020.}

Lectins bind selected carbohydrate structures. Dolichos biflorus anti-A₁ and Ulex europaeus anti-H support ABO subgroup investigations under their reagent instructions. Interpret their patterns with forward and reverse grouping, reaction strength, and the patient's history.^{11 Bloch EM, et al. Technical Manual. 2026.}

Adsorption and elution

When a broadly reactive antibody reacts with every panel cell, adsorption can remove it so that an underlying alloantibody can be detected. Adsorption removes selected antibody from serum or plasma by binding it to cells or another antigen-bearing material. Test the adsorbed specimen for reactivity that the removed antibody had masked.

Antibody titration

Titration estimates relative antibody concentration through twofold serial dilutions. The reported titer is the reciprocal of the highest dilution that meets the laboratory's defined reaction endpoint. An optional score assigns values to every reaction grade and adds them across the dilution series, which can reveal a change spread across several tubes or wells.^{1,41 Bloch EM, et al. Technical Manual. 2026.4 Raman L, et al. Principles of laboratory techniques. 2020.}

Serial comparison requires the same validated method, endpoint, reagent-cell phenotype, cell source, and test conditions. Test the stored baseline specimen beside the current specimen when possible. Prepare dilutions in the direction specified by the procedure and use calibrated pipettes to limit carryover and volume error. Tube, column, and solid-phase titers can produce different numeric endpoints, so the report includes the method used.^{44 Raman L, et al. Principles of laboratory techniques. 2020.}

One commonly used score assigns 12 to 4+, 10 to 3+, 8 to 2+, and 5 to 1+. Within that scoring system, a change of 10 or more is commonly treated as significant. The procedure must name the adopted score and its validated cutoff. Separating passive from immune anti-D requires Rh immune globulin history, timing, the reaction pattern, and the trend. The HDFN titer section connects the laboratory result with fetal-risk assessment.^{11 Bloch EM, et al. Technical Manual. 2026.}

Mixed red-cell populations and molecular testing

Recent transfusion can place donor and patient red cells in the same specimen. Serologic antigen typing then reflects both populations. Reference laboratories may enrich a patient-cell fraction. Each method has limits on how completely it separates the populations.

Neutralization and thiol reagents

Neutralization uses soluble antigen to bind one antibody in a serum or plasma mixture. Divide the specimen into a neutralized aliquot and a dilution-control aliquot. The control receives an equal volume of saline or the control material named by the procedure. Loss of reactivity only in the neutralized aliquot supports inhibition of the targeted antibody. Investigate any remaining reactivity for clinically significant alloantibodies.^{1,41 Bloch EM, et al. Technical Manual. 2026.4 Raman L, et al. Principles of laboratory techniques. 2020.}

High-titer, low-avidity (HTLA) describes a serologic pattern of weak, broad AHG reactivity against high-prevalence antigens. Classical examples include antibodies in the Chido/Rodgers, Knops, and JMH systems. These antibodies usually have little effect on red-cell survival, but their broad reactivity can mask a clinically significant alloantibody. Neutralization, selected enzyme effects, thiol treatment, rare cells, and reference-laboratory testing help define the interference.^{11 Bloch EM, et al. Technical Manual. 2026.}

Dithiothreitol (DTT) and 2-mercaptoethanol reduce disulfide bonds and can disperse IgM pentamers in a treated serum aliquot. Compare treated and untreated aliquots under one validated method when the laboratory question is whether IgM or IgG accounts for reactivity. The result depends on reagent concentration, exposure time, temperature, and controls. When the dilution control remains reactive, a known IgM control loses activity, and an IgG control retains activity, loss of the patient's reactivity supports an IgM contribution. A nonreactive treated aliquot shows only that no IgG reactivity was detected. Weak IgG may remain below the method's detection limit. The reagent red cells remain untreated in this serum-treatment comparison.^{1010 Okuno T, et al. Evaluation of dithiothreitol (DTT) for inactivation of IgM… 1978.}

DTT treatment of reagent red cells has a different purpose. It removes anti-CD38 therapeutic interference by destroying CD38 on the cells, and it also destroys Kell and weakens or destroys other DTT-sensitive antigens. AABB's updated 2026 guidance recommends K-negative units after DTT-based testing unless the patient is known to be K-positive. Antibodies to k, Yt^a, Dombrock, and other DTT-sensitive antigens may not be detected. Baseline or current genotyping, the antibody history, DTT-treated controls, and the approved unit-selection process help address this residual risk.^{1111 Association for the Advancement of Blood &… Association Bulletin #16-02. 2026.}

Column and solid-phase endpoints

Tube, column-agglutination, and solid-phase methods create different visible endpoints. The reagent card, plate, instrument, and instructions for use define the analyte, controls, cell concentration, incubation, centrifugation, wash sequence, and grading rules.^{12,1312 Bio-Rad Medical Diagnostics GmbH. Solidscreen II Microplate for Solid Phase Antiglobulin Tests…13 Diagnostic Grifols, et al. DG Gel 8 Cards Instructions for Use.}

Column agglutination

In a column card, plasma or serum and reagent cells incubate in the reaction chamber above the gel. Centrifugation then moves unagglutinated cells through the porous matrix to a pellet at the bottom. Agglutinates remain near the top or disperse through the column according to their size. A mixed-field result contains an agglutinated population in the column and an unagglutinated pellet at the bottom. Reaction grades and matrix composition are product-specific.^{1313 Diagnostic Grifols, et al. DG Gel 8 Cards Instructions for Use.}

Read the card within the product's stated interval. Fibrin, particulates, rouleaux, incorrect cell concentration, drying, and improper centrifugation can create anomalous patterns. Patient transfusion and transplantation history helps determine whether a mixed-field reaction represents two real cell populations. Correlate the pattern with card quality and specimen findings. Column methods incorporate separation within the matrix and use their own positive and negative quality controls.^{1313 Diagnostic Grifols, et al. DG Gel 8 Cards Instructions for Use.}

Solid phase

Solid-phase formats bind red-cell membrane, antigen, antibody, or Protein A to a microplate well. In one FDA-authorized Protein A format, patient serum or plasma and reagent red cells incubate in the coated well. Washing removes unbound protein, anti-IgG links sensitized cells, and centrifugation produces a smooth cell layer for a positive reaction. Unsensitized cells form a compact central button. Other systems use red-cell membrane-coated wells and indicator cells, so the endpoint and controls are specific to that assay.^{1212 Bio-Rad Medical Diagnostics GmbH. Solidscreen II Microplate for Solid Phase Antiglobulin Tests…}

Each solid-phase system has defined indications for antibody screening, identification, crossmatch, DAT, or antigen typing. The product label defines the analyte. Platelet and HLA enzyme-linked or multiplex assays use related surface-bound principles with their own antigen panels and signal systems. Interpret the assay through its named analyte, controls, and intended use.

Chloroquine and EGA treatment

An IgG-positive DAT can interfere with antigen typing that uses an IAT phase. Chloroquine diphosphate and EDTA-glycine-acid (EGA) are partial-elution treatments that can remove cell-bound IgG and leave the cells suitable for selected antigen studies. Their antigen effects differ.^{1,41 Bloch EM, et al. Technical Manual. 2026.4 Raman L, et al. Principles of laboratory techniques. 2020.}

Confirm IgG removal with monospecific anti-IgG after chloroquine treatment because complement can remain and react with polyspecific AHG. Test a known antigen-positive cell through the same treatment when the method requires it. Exposure time, temperature, reagent concentration, and overtreatment limits belong in the procedure. After recent transfusion, the treated cells remain unreliable for assigning the patient's inherited phenotype, even after the coating antibody is removed. Use genotyping or reference-laboratory testing to resolve that problem. For every method, record what it removed or altered so that later reviewers know which antibodies it could not exclude.^{1,51 Bloch EM, et al. Technical Manual. 2026.5 Johnson ST, et al. Evaluating patients with autoimmune hemolytic anemia in the… 2022.}

Practice